Treatment of breast cancer during pregnancy: Regimen selection, pregnancy monitoring and more ...

Breast

Volumn 20, Issue 1, 2011, Pages 1-6

  Azim, H A ^a   Del Mastro, L ^b   Scarfone, G ^c   Peccatori, F A ^d  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer during pregnancy; Chemotherapy; Safety; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; NAVELBINE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE; VINCA ALKALOID;

ADJUVANT THERAPY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; FETUS MONITORING; HEMATOLOGIC MALIGNANCY; HUMAN; MATERNAL MORBIDITY; MULTIPLE CYCLE TREATMENT; OSTEOPOROSIS; OVERALL SURVIVAL; PATIENT COUNSELING; PATIENT MONITORING; PREGNANCY; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; TERATOGENICITY;

EID: 79451473327     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.10.008     Document Type: Review

References (50)

1. Nugent P., O'Connel T.X. Breast cancer and pregnancy. Arch Surg 1985, 120:1221-1224.
2. Berkowitz G.S., Skovron M.L., Lapinski R.H., Berkowitz R.L. Delayed childbearing and the outcome of pregnancy. N Engl J Med 1990, 322:639-664.
3. Haas J.F. Pregnancy is association with newly-diagnosed cancer: a population-based epidemiologic assessment. Int J Cancer 1989, 34:229-235.
4. Ní Mhuireachtaigh R., O'Gorman D.A. Anesthesia in pregnant patients for nonobstetric surgery. J Clin Anesth 2006, 18:60-66.
5. Moran B.J., Yano H., Al Zahir N., Farquharson M. Conflicting priorities in surgical intervention for cancer in pregnancy. Lancet Oncol 2007, 8:536-544.
6. Orecchia R., Lucignani G., Tosi G. Prenatal irradiation and pregnancy: the effect of diagnostic imaging and radiation therapy. Recent Results Cancer Res 2008, 178:3-20.
7. Barthelmes L., Gateley C.A. Tamoxifen and pregnancy. Breast 2004, 13:446-451.
8. Loibl S., von Minckwitz G., Gwyn K., Ellis P., Blohmer J.U., Schlegelberger B., et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer 2006, 106:237-246.
9. Williams S., Schilsky R.L. Antineoplastic drugs administered during pregnancy. Sem Oncol 2000, 27:618-622.
10. Cardonick E., Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004, 5:283-291.
11. Doll R.C., Ringenberg Q.S., Yarbo J.W. Antineoplastic agents and pregnancy. Semin Oncol 1989, 16:337-345.
12. Zemlickis D., Lishner M., Degendorfer P., Panzarella T., Sutcliffe S.B., Koren G. Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med 1992, 152:573-576.
13. Ebert U., Loffler H., Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther 1997, 74:207-220.
14. Woo J.C., Yu T., Hurd T.C. Breast cancer in pregnancy: a literature review. Arch Surg 2003, 138:91-98.
15. Williams S.F., Britan J.D. Cancer and pregnancy. Clin Perinatol 1985, 12:609-623.
16. Azim H.A., Peccatori F.A., Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: solid tumors. Cancer Treat Rev 2010, 36:101-109.
17. Ring A.E., Smith I.E., Jones A., Shannon C., Galani E., Ellis P.A. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol 2005, 23:4192-4197.
18. Hahn K.M., Johnson P.H., Gordon N., Kuerer H., Middleton L., Ramirez M., et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006, 107:1219-1226.
19. Peccatori F.A., Azim H.A., Scarfone G., Gadducci A., Bonazzi C., Gentilini O., et al. Weekly epirubicin in the treatment of gestational breast cancer (GBC). Breast Cancer Res Treat 2009, 115:591-594.
20. Cardonick E., Dougherty R., Grana G., Gilmandyar D., Ghaffar S., Usmani A. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J 2010, 16:76-82.
21. Loibl S., Bontenbal M., Ring A., Kaufmann M., Crivellari D., Fehm T., et al. Breast cancer during pregnancy - a prospective and retrospective European registry (GBG-20/BIG02-03). Eur J Cancer 2010, 8. abstract # 499.
22. Nabholtz J.M., Gligorov J. The role of taxanes in the treatment of breast cancer. Expert Opin Pharmacother 2005, 6:1073-1094.
23. Mir O., Berveiller P., Ropert S., Goffinet F., ons G., Treluyer J.M., et al. Emerging therapeutic options for breast cancer during pregnancy. Ann Oncol 2008, 19:607-613.
24. Anderson G.D. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005, 44:989-1008.
25. Mir O., Berveiller P., Goffinet F., Treluyer J.M., Serreau R., Goldwasser F., et al. Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol 2010, 21:425-426.
26. Pereg D., Lishner M. Maternal and fetal defects of systemic therapy in the pregnant woman with cancer. Recent Results Cancer Res 2008, 178:21-38.
27. Tradeau M., Charbonneau F., Gelmon K., Laing K., Latreille J., Mackey J., et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 2005, 6:886-898.
28. Azim H.A., Peccatori F.A. Treatment of cancer during pregnancy: the need for tailored strategies. J Clin Oncol 2010, 28:e302-303.
29. Green M.C., Buzdar A.U., Amith T., Ibrahim N.K., Valero V., Rosales M.F., et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005, 23:5983-5992.
30. Sparano J.A., Wang M., Martino S., Jones V., Perez E.A., Saphner T., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358:1663-1671.
31. Azim H.A., Pavlidis N., Peccatori F.A. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: hematological tumors. Cancer Treat Rev 2010, 36:110-121.
32. Mir O., Berveiller P., Ropert S., Goffinet F., Goldwasser F. Use of platinum derivatives during pregnancy. Cancer 2008, 113:3069-3074.
33. Coleman R., Gnant M. New results from the use of bisphosphonates in cancer patients. Curr Opin Support Palliat Care 2009, 3:213-218.
34. Minsker D.H., Manson J.M., Peter C.P. Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 1993, 121:217-223.
35. Djokanovic N., Klieger-Grossmann C., Koren G. Does treatment with bisphosphonates endanger the human pregnancy?. J Obstet Gynaecol Can 2008, 30:1146-1148.
36. Levy S., Fayez I., Taguchi N., Han J.Y., Aiello J., Matsui D., et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone 2009, 44:428-430.
37. Azim H., Azim H.A. Targeting Her-2/neu in breast cancer: as easy as this!. Oncology 2008, 74:150-157.
38. Azim H.A., Peccatori F.A., Liptrott S.J., Catania C., Gldhirsch A. Breast cancer and pregnancy: how safe is trastuzumab?. Nat Rev Clin Oncol 2009, 6:367-370.
39. Azim H.A., Azim H., Peccatori F.A. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol 2010, 6:821-826.
40. Pentsuk N., van der Laan J.W. An interspecies comparison of placental antibody transfer: new insights into development toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 2009, 86:328-344.
41. Van Calsteren K., Heyns L., De Smet F., Van Eycken L., Gziri M.M., Van Gemert W., et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and neonatal outcome. J Clin Oncol 2010, 28:683-689.
42. Colleoni M., Bonetti M., Coates A., Castiglione-Gertsch M., Gelber R.D., Price K., et al. Early start of adjuvant chemotherapy may improve treatment out come for premenopausal breast cancer patients with tumors not expressing estrogen receptors. J Clin Oncol 2000, 18:584-590.
43. Recht A., Come S.E., Henderson I.C., Gelman R.S., Silver B., Hayes D.F., et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996, 334:1356-1361.
44. Beadle B.M., Woodward W.A., Middleton L.P., Tereffe W., Strom E.A., Litton J.K., et al. The impact of pregnancy on breast cancer outcome in women > = 35 years. Cancer 2009, 115:1174-1184.
45. World Health Organization The prevention of perinatal mortality and morbidity 1970, WHO technical Report Series, Geneva, Switzerland, Report 457.
46. Goldenberg R.L., Culthane J.F., Iams J.D., Romero R. Epidemiology and causes of preterm birth. Lancet 2008, 371:75-84.
47. Saigal S., Doyle L.W. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 2008, 371:261-269.
48. Huddy C.L., Johnson A., Hope P.L. Educational and behavioral problems in babies of 32-35 weeks gestation. Arch Dis Child Fetal Neonaltal Ed 2001, 85:F23-F28.
49. Moster D., Lie R.T., Markestad T. Long-term medical and social consequences of preterm birth. N Engl J Med 2008, 359:262-273.
50. Pavlidis N., Pentheroudakis G. The pregnant mother with breast cancer: diagnostic and therapeutic management. Cancer Treat Rev 2005, 31:439-447.